2005 DDW abstract highlights
	2006 DDW CME satellite symposium on TNF antagonists
	2006 ACG CME satellite symposium on TNF antagonists
	2007 DDW CME satellite symposium on innovative strategies for biologic therapies in Crohn's disease
	2007 ACG satellite symposium

Detection of intraepithelial neoplasia and colon cancer

Screening for p53 and K-ras mutations

	A systematic review of collagenous colitis
	Long-term colectomy rates after infliximab therapy
	Multicenter double-blind trial of budesonide in collagenous colitis
	Case-control study of association with non-steroidal anti-inflammatory drug (NSAID) use
	Weekend 5-aminosalicylic acid (ASA) enema maintenance therapy

	Adalimumab induction therapy
	Adalimumab maintenance therapy
	Adherence to thiopurines and mesalamine in children
	Antibiotic treatment
	Anti-interleukin-12 therapy
	Assessment of imaging techniques for small bowel disease
	Association of perianal disease with intestinal fistulization
	Autologous hematopoietic stem cell transplantation
	Azathioprine maintenance
	Birth outcomes in Danish women related to therapy of women with CD
	Budesonide for maintenance remission therapy
	Capsule endoscopy vs. enteroclysis
	Certolizumab pegol as treatment for Crohn’s disease (CD)
	Combined budesonide and antibiotic therapy
	Defining contributions of gene mutations, age at onset, and tobacco use
	Effect of infliximab on resource use
	Enteral nutrition (EN) as therapy in children with Crohn’s disease (CD).
	CD after allogeneic stem cell transplantation
	CD medication and birth outcomes
	CD patients’ relatives with subclinical intestinal inflammation
	Change in diagnosis from ulcerative colitis (UC) to Crohn’s disease (CD).
	Confirmation of the role of ATG16L1
	Combination antibiotic therapy in Crohn’s disease
	Conventional vs. laparoscopic ileocolic resection
	Corticosteroid therapy increases the risk for intra-abdominal or pelvic abscess
	Detection of postsurgical Crohn’s disease recurrence
	Diagnosis and management of CD
	Double-balloon endoscopy and capsule endoscopy
	Effects of 5-aminosalicylates (5-ASAs) on renal function
	Effects of budesonide and prednisolone on bone mineral density
	Elevated vitamin D levels in CD
	Ethical issues concerning therapeutic studies
	Exposure to diagnostic medical radiation
	Expression of I2 antibodies predicts response to fecal diversion
	Factors that influence progressive disease behavior
	Familial Mediterranean fever gene prevalence
	Fontolizumab dose-escalation studies
	Guide to infliximab treatment
	Immunosuppressive drugs decrease recurrence rate after second resection
	Immunosuppressive therapy reduces the formation of antibodies to infliximab
	Impact of immunosuppressant therapies
	Incidence of Clostridium difficile infection
	Increased risk for carcinoid tumors
	Ineffectiveness of probiotics
	Inflammatory CD and the effect of tobacco consumption
	Infliximab maintenance therapy for fistulizing CD
	Infliximab: maintenance for life vs episodic therapy
	Infliximab for pediatric CD
	Infliximab-induced autoantibodies
	Infliximab trough serum level predicts outcomes
	Laparoscopic ileocolic resection
	Localization of anal fistulas
	Long-term fracture risk
	Long-term outcomes after colonoscopic balloon dilation of strictures
	Long-term outcomes after corticosteroid-induced remission
	Long-term results of ileocecal resection
	Magnetic resonance imaging (MRI) of effects of infliximab therapy
	Maintenance budesonide therapy
	Maintenance infliximab therapy
	Maintenance therapy with adalimumab
	Medication adherence
	Mercaptopurine following intolerance to azathioprine
	Mesalamine formulation determines effectiveness
	Meta-analyses of CD studies
	Methotrexate (MTX) in pediatric CD patients
	Mortality by inflammatory bowel disease (IBD) medication use
	Mortality 10 years after diagnosis
	Natalizumab therapy
	Natalizumab maintenance therapy
	Natalizumab treatment for active Crohn’s disease (CD)
	Natalizumab and progressive multifocal leukoencephalopathy
	Novel serologic markers
	NOD2/CARD15 does not influence response to infliximab
	Open-label study of adalimumab
	Oral manifestations
	Ornidazole prophylaxis
	Osteoporotic vertebral fractures
	Phenotype predicts recurrence rates
	Pilot study anti-interleukin (IL)-6 receptor monoclonal antibody therapy
	Pitfalls in interpretation of non-neoplastic mucosal biopsy specimens
	Placebo response and remission rates
	Postoperative therapy
	Predictors of Crohn’s disease
	Predictors of response to infliximab
	Pregnancy and disease activity
	Prevalence of Mycobacterium avium subspecies paratuberculosis (MAP) in intestinal mucosal biopsies
	Prognostic studies
	Push-and-pull enteroscopy
	Race and health insurance are predictors for bowel resection
	Randomized study of adalimumab therapy
	Rising hospitalization rates for IBD
	Risk of vertebral fractures
	Risk factors for colorectal neoplasia
	Risk factors for initial surgery in a pediatric population
	Risk for intestinal cancer
	Role of intestinal microflora
	Role of organic cation transporter gene polymorphism
	Safety profile of infliximab
	Small-bowel adenocarcinoma
	Steroid injection after dilation of anastomotic strictures
	Risk of early surgery
	Risk factors for the development of stricturing or penetrating disease
	Serum immune response in children as a predictor of disease progression
	Surgical vs. percutaneous drainage of abdominal and pelvic abscesses
	Survival after colorectal cancer
	Swedish twin study
	Tacrolimus for the treatment of fistulas
	The hygiene hypothesis
	Thiopurine S-methyltransferase (TPMT) deficient CD patients and azathioprine therapy
	Treatment with granulocyte-macrophage colony-stimulating factor
	Trial of certolizumab
	Trial of Lactobacillus GG in addition to standard maintenance therapy in children with CD
	Trial of sargramostim
	Wireless capsule endoscopy

	Factors affecting cost and length of hospitalization
	Probiotic therapy

	6-thioguanine
	6-thioguanine nucleotide (6-TGN) levels
	Acute gastroenteritis and risk of IBD
	Allopurinol in azathioprine (AZA) or 6-mercaptopurine (6-MP) failures
	Aminosalicylates and colorectal cancer in IBD: a review
	Antibodies as predictors of IBD
	Arterial thromboembolic diseases
	Assessment of thrombin-activatable fibrinolysis inhibitor
	Association of azathioprine toxicity with gene polymorphisms
	Association of antibody reactivity to microbial antigens with small bowel complications
	Associated osteopenia.
	Azathioprine and 6-mercaptopurine (6-MP) and risk of lymphoma
	Budesonide treatment of collagenous colitis
	Budesonide treatment.
	Cyclosporine
	Cytomegalovirus (CMV) colitis
	Capsule endoscopy retention
	Complementary alternative medicine
	Consensus conference
	Concerns of patients with inflammatory bowel disease and an ileostomy
	Correlation of azathioprine thioguanine nucleotide metabolite levels and disease activity
	Corticosteroids and immunomodulators: postoperative risks for infection
	Corticosteroid use and bone fracture
	Discriminating IBD from irritable bowel syndrome (IBS)
	Do life events trigger IBD relapse?
	Do patients receive optimal care?
	Effects of appendectomy
	Effect of smoking on phenotype
	Efficacy and safety of thalidomide
	Enteric infection at relapse
	Epithelial barrier disruption and intestinal inflammatory response
	Familial transmission of CARD15
	Genetics of IBD
	Guidelines for immunizations in patients with IBD
	Gut barrier function
	Hepatosplenic T-cell lymphoma (HSTCL) following infliximab.
	Herpes zoster incidence
	HLA disparity and disease activity
	Hormonal replacement therapy (HRT)
	IBD and pregnancy
	IBD-associated gastrointestinal cancer: Prognosis and risk
	IBD in children under 5 years of age
	IBD is not a risk factor for cardiovascular (CV) disease mortality
	IBD-related osteonecrosis
	IBD summer camp and improvement in health-related quality of life
	Immune-mediated disease clustering in IBD patients
	Impact of IBD on labor force
	Impact of IBD on women
	Impact of race and ethnicity
	Immune responses to influenza vaccine
	Immunosuppression: A role in the management and development of inflammatory bowel disease
	Increased risk for demyelinating and other inflammatory diseases
	Indeterminate colitis
	Ineffective biologics
	Iron deficiency anemia
	Iron therapy
	Laboratory markers
	Long-term follow-up of tacrolimus therapy
	Long-term nonsteroidal anti-inflammatory drugs (NSAIDs) activity
	Mortality in IBD
	Neoplasms after 6-mercaptopurine
	Nonsteroidal antiinflammatory drug treatment of IL-10-deficient mice
	Nonsteroidal anti-inflammatory drugs (NSAIDs) and colonic ulcers
	Only non-specific inhibitors of both cyclooxygenase (COX)-1 and COX-2 induce IBD flares
	Oral iron therapy in IBD
	Oral medication adherence in a pediatric population
	Patient nonadherence to medication
	Patient-orientated self management
	Pediatric Crohn's disease
	Pediatric intermediate colitis
	Pediatric therapies for inflammatory bowel disease
	Pharmacogenomic studies during thiopurine therapy
	Pharmacokinetic effect of mesalazine on mercaptopurine metabolites
	Pregnancy outcomes
	Prevalence of anemia
	Report on the vitamin D status of IBD patients
	Reproduction in patients with IBD
	Reviews
	Risk for lymphoma
	Risk for thromboembolism
	Risk of developing IBD is affected by having siblings
	Role of smoking
	Safety of 6-mercaptopurine (6-MP) for childbearing patients
	Seasonal variation of flares
	Survival and causes of mortality
	Targeting selective adhesion molecules
	The effect of iron therapy for anemia on quality of life
	Thiopurine-induced liver injury
	Thiopurine methyltransferase (TPMT) enzyme activity is predictive of azathioprine-induced myelosuppression.
	Total and cancer mortality in UC vs. CD patients
	Treatment of anemia with intravenous iron sucrose
	Uveitis and erythema nodosum in IBD
	Work losses related to IBD

	A comparison of infliximab treatment strategies
	Antibody formation to infliximab
	Antibody responses to infliximab
	Association between response to infliximab and type of fistula
	Associated autoimmunity
	CDC warns physicians who prescribe TNF-alpha antagonists to monitor patients for TB
	Effects of infliximab maintenance therapy on quality of life
	High incidence of anergy
	Induction of tolerance to infliximab in patients with prior severe infusion reactions
	Infliximab management for CD of the ileal-pouch anastomosis
	Infliximab and risk of latent virus reactivation
	Infliximab management of ulcerative colitis
	Infliximab plus azathioprine (AZA)/6-mercaptopurine (MP)
	Infliximab therapy adherence in CD
	Infliximab therapy and pregnancy outcomes
	Infliximab use is not associated with an increased risk of neoplasia
	Influence of immunogenicity
	Lack of postoperative complications in CD patients
	Long-term safety data for patients treated with infliximab
	Patient perceptions of infliximab
	Population-based cohort safety study
	Relationship with the onset of granulomatous infection
	Risk-benefit analysis of infliximab therapy
	Transplacental transfer of infliximab

	Daclizumab therapy of active ulcerative colitis
	Pulse cyclophosphamide

Probiotic therapy for recurrent or refractory pouchitis

	Infliximab therapy (November 2002)
	Infliximab therapy (October 2003)

Long-term infliximab treatment

	5-aminosalicylate (ASA) use and the development of colorectal cancer
	5-aminosalicylate (ASA) use and colorectal cancer risk
	Adenoma-like dysplasia-associated lesions or masses (DALMs): long-term follow-up after polypectomy
	Assessment of rectal mucosa by magnifying colonoscopy
	Azathioprine vs. azathioprine plus olsalazine
	Azathioprine vs 5-aminosalicylic acid
	Balsalazide therapy associated with more rapid improvements
	Blockade of cellular adhesion molecules
	Chromoscopic endomicroscopy vs chromoscopy alone
	Clinical course of distal UC
	Colectomy rates in a European cohort
	Combined oral and enema treatment with mesalamine
	Continuous Infusion vs. bolus administration of steroids
	Controversies in IBD
	Curcumin maintenance therapy
	Cyclosporine therapy
	Cytomegalovirus infection
	DNA fingerprinting abnormalities
	Dose-finding study of alicaforsen enemas
	Dose-finding study of oral tacrolimus
	Effectiveness of 5-amino-salicylic acid (5-ASA) enemas
	Effectiveness of colorectal cancer surveillance
	Endoscopic cancer surveillance in ulcerative colitis
	Endoscopic mucosal resection (EMR) of flat neoplasia
	Epidermal growth factor (EGF) enema therapy
	Experience with infliximab in childhood UC
	Factors associated with colorectal cancer
	Factors associated with a decrease in the extent of disease
	Female fertility after ileal pouch-anal anastomosis
	Follow-up of patients with low-grade dysplasia
	High concentration multimatrix system (MMX) mesalamine
	High-dose vs. low-dose cyclosporine
	Higher-dose mesalamine
	Histologic inflammation is a risk factor for progression to neoplasia